Join the #tALKpositiveNSCLC Conversation and Pay It Forward

About tALK+

tALK+ (TALK positive) is an initiative that highlights the positive experiences and personal stories of those impacted by non-small cell lung cancer (NSCLC).

Join Takeda Oncology throughout Lung Cancer Awareness Month (November) and on ALK+ Day, November 13, created to spread awareness and educate about ALK+ NSCLC, including common misconceptions. The goal of tALK+ is to spread positivity throughout the NSCLC community on social media.

Pay it forward by joining the #tALKpositiveNSCLC conversation on social media and sharing positive stories about the NSCLC community.

Join the Conversation

Use the hashtag #tALKpositiveNSCLC and join the conversation on social media or follow @TakedaOncology to learn more facts about ALK+ NSCLC

Understanding ALK+ NSCLC and Its Genetic Variations

NSCLC is the most common form of lung cancer, accounting for approximately 85% of the estimated 235,760 new cases of lung cancer diagnosed in the United States according to the National Cancer Institute.

Lung cancer develops in different ways in different people. There are many subtypes of lung cancer caused by different genetic changes, or mutations. Your doctor can test you to see what type of genetic mutation you may have. That will help them decide what type of treatment to give you.

*These numbers are from people with adenocarcinoma NSCLC, the most common type of NSCLC.

In some people, lung cancer is caused by a mutation in what's called the ALK gene. About 3% to 5% of people with adenocarcinoma* non-small cell lung cancer (NSCLC) have this mutation. This means somewhere between 4,700 and 7,100 people who get lung cancer each year have ALK+ NSCLC.
When people hear about someone with lung cancer, they often assume that person used to smoke cigarettes. While there is a well-established link between smoking and lung cancer, most people with ALK+ NSCLC actually either never smoked or rarely smoked.

You are now leaving Living With ALK.

This link will take you to, a patient registry designed for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Yes, I want to continue No, I want to stay here